UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Zachary Klaassen speaks with Jie Luo about his Prostate Cancer Foundation Young Investigator Award work on androgen receptor enhanceosomes in prostate cancer. Dr. Luo explains that enhanceosomes are ...

Zachary Klaassen is joined by Rahul Aggarwal to discuss final results from the PRESTO trial evaluating treatment intensification for high-risk biochemically recurrent prostate cancer. The trial ...

Carissa Chu discusses her Prostate Cancer Foundation Young Investigator Award work on STEAP1-targeted bispecific T-cell engagers. Dr. Chu explains that STEAP1, a six-transmembrane surface protein, is ...

Andrew Hahn discusses HLD-0915, a first-in-class Regulated Induced Proximity TArgeting Chimera (RIPTAC™) therapy for metastatic castration-resistant prostate cancer. Dr. Hahn explains that RIPTACs ...

Chronic prostatitis/chronic pelvic pain syndrome: Interplay of inflammatory mediators, "Beyond the Abstract," by Dan Lundh, Hans Hedelin, and Dennis Larsson ...

Varicocele and Sperm DNA Fragmentation: New Evidence with Implications for Clinical Practice - Beyond the Abstract ...

(UroToday.com) At the metastatic prostate cancer session at the European Association of Urology 2021 Virtual Meeting, Dr. Simon Chowdhury presented results of outcomes in high and low-volume disease ...

(UroToday.com) The 2022 American Urological Association Annual Meeting included a prostate cancer session featuring work from Dr. Mohammad Siddiqui and colleagues presenting results of their study ...

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...

Rashid Sayyid and Zachary Klaassen discuss the 2024 updates to the NCCN guidelines for metastatic castration-resistant prostate cancer (mCRPC) treatment. They review the current management algorithm, ...

Giulia Marvaso discusses the RADIOSA trial, a phase II randomized study comparing SBRT alone versus SBRT with short-course hormonal therapy for oligorecurrent prostate cancer. The trial includes 102 ...